Table 1. Baseline characteristics of all female patients aged 16-50 years starting antiretroviral therapy (ART) since 01/09/2011 in 19 facilities with electronic medical record systems.
| Total |
Non-pregnant women starting ART for their own health |
Pregnant women starting ART due to Option B+ |
Breastfeeding women starting ART due to Option B+ |
|
|---|---|---|---|---|
| Number of patients | 11534 | 6177 | 3320 | 2037 |
| Median (IQR) age (years) | 30.4 (25.9-35.8) | 33.1 (28.3-38.8) | 27.9 (23.8-31.7) | 28.4 (24.6-32.5) |
| < 30 (%) | 5 466 (47.4) | 2058 (33.3) | 2143 (64.6) | 1265 (62.1) |
| 30-39 (%) | 4658 (40.4) | 2835 (45.9) | 1109 (33.4) | 714 (35.1) |
| ≥40 (%) | 1410 (12.2) | 1284 (20.8) | 68 (2.1) | 58 (2.9) |
| ART eligibility due to CD4 cell count (%) | ||||
| eligible | 2853 (24.7) | 2731 (44.2) | 39 (1.2) | 10 (0.5) |
| not eligible | 117 (1.0) | 50 (0.8) | 112 (3.7) | 28 (1.4) |
| missing1 | 8564 (74.3) | 3396 (55.0) | 3169 (95.5) | 1999 (98.1) |
| WHO clinical stage (%) | ||||
| Stage 1 | 3072 (26.6) | 2052 (33.2) | 1020 (30.7) | 0 (0.0) |
| Stage 2 | 494 (4.3) | 434 (7.0) | 60 (1.8) | 0 (0.0) |
| Stage 3 | 3336 (28.9) | 3239 (52.4) | 97 (2.9) | 0 (0.0) |
| Stage 4 | 465 (4.0) | 452 (7.3) | 13 (0.4) | 0 (0.0) |
| missing | 4167 (36.1) | 0 (0.0) | 2130 (64.2) | 2037 (100.0) |
|
ART eligible due to CD4≤350/μL or
WHO stage3/4 (%) |
||||
| eligible | 6370 (55.2) | 6142 (99.4) | 218 (6.6) | 10 (0.5) |
| not eligible or missing | 5164 (44.8) | 35 (0.6) | 3102 (93.4) | 2027 (99.5) |
| HIV testing date missing (%) | 1355 (11.8) | 827 (13.4) | 288 (8.7) | 240 (11.8) |
| Year of ART start (%) | ||||
| 2011 | 5735 (49.7) | 2901 (47.0) | 1590 (47.9) | 1244 (61.1) |
| 2012 | 5799 (50.3) | 3276 (53.0) | 1730 (52.1) | 793 (38.9) |
| Number (%) pregnant | 3320 (28.8) | 0 (0.0) | 3320 (100.0) | 0 (0.0) |
| Most frequent ART regimen (%) | ||||
| d4T 3TC NVP | 5819 (50.5) | 5479 (88.7) | 179 (5.4) | 161 (7.9) |
| TDF 3TC EFV | 5420 (47.0) | 488 (7.9) | 3090 (93.1) | 1842 (90.4) |
IQR: interquartile range; d4T: stavudine; 3TC: lamivudine NVP: nevirapine; TDF: tenofovir; EFV: efavirenz
1
ART eligibility assessment due to CD4 cell count was missing if no CD4 cell count was measured between 3 months before and 1 month after start of antiretroviral therapy.